Cargando…
p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act
Doxorubicin (DOX) is a highly effective chemotherapeutic drug, but its long-term use can cause cardiotoxicity and drug resistance. Accumulating evidence demonstrates that p53 is directly involved in DOX toxicity and resistance. One of the primary causes for DOX resistance is the mutation or inactiva...
Autores principales: | Guo, Yuanfang, Tang, Yufeng, Lu, Guangping, Gu, Junlian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222243/ https://www.ncbi.nlm.nih.gov/pubmed/37242146 http://dx.doi.org/10.3390/nu15102259 |
Ejemplares similares
-
Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2
por: Wang(a), Jie, et al.
Publicado: (2022) -
A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity
por: Xiao, Mengjie, et al.
Publicado: (2021) -
Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway
por: Lu, Guangping, et al.
Publicado: (2022) -
Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity
por: McSweeney, K. Melodi, et al.
Publicado: (2019) -
Harpagoside Protects Against Doxorubicin-Induced Cardiotoxicity via P53-Parkin-Mediated Mitophagy
por: Li, Weili, et al.
Publicado: (2022)